Zenith Epigenetics Commences Operations
News Jun 05, 2013
Zenith Epigenetics Corp. has commenced operations as an early stage research company. Zenith was formed as a result of a plan of arrangement (the "Arrangement") involving Resverlogix Corp. ("Resverlogix"), RVX Therapeutics Inc. ("Therapeutics") and Zenith pursuant to which Resverlogix spun-out Therapeutics to Zenith.
Shareholders of Resverlogix now own one new common share of Resverlogix and one common share of Zenith for each common share of Resverlogix held immediately prior to the Arrangement becoming effective.
Pursuant to the Arrangement, Resverlogix retained its research and development activities related to the development of compounds for applications with indications involving a therapeutic increase in Apolipoprotein A-1 (ApoA-I), including the clinical program related to RVX-208, a first in class small molecule for the treatment of atherosclerosis and Resverlogix completed the spin-off of all other research and development activities related to its epigenetic platform technology to Zenith.
Pursuant to the Arrangement, Zenith was also issued royalty preferred shares in the capital of Resverlogix which will provide Zenith with a dividend equal to six to twelve percent of "Net Apo Revenue" as described in the Information Circular of Resverlogix dated April 29, 2013.
As part of the Arrangement, Resverlogix also transferred to Zenith all of the indebtedness of Therapeutics owing to Resverlogix as well as $10 million in cash to provide for the initial capitalization of Zenith.
Management and Directors
The management team of Zenith will be led by the management team of Resverlogix, including Donald McCaffrey as President and Chief Executive Officer, Brad Cann as Chief Financial Officer, Kenneth Lebioda as Senior VP Business & Corporate Development, Dr. Norman Wong, as Chief Scientific Officer and Chairman of the Scientific Advisory Board, Dr. Jan Johansson, as Senior VP Medical Affairs, Dr. Gregory Wagner, as Senior VP Research and Development and Dr. Allan Gordon, as Senior VP Clinical Development.
The board of directors of Zenith consists of Dr. Peter Johann, Donald McCaffrey, Kenneth Zuerblis, Dr. Eldon Smith, Kelly McNeill and Arthur J. Higgins.
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
Cow Antibodies Yield Important Clues For Developing A Broadly Effective AIDS VaccineNews
The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.READ MORE